Metformin vs MOTS-c
FDA Approved vs Well Studied
monitor Researched · 90% Both activate AMPK; monitor for additive hypoglycemic effects.
Molecular Data
Metformin MOTS-c
Weight 129.16 Da 2,174.6 Da
Half-life ~5 hours ~30 minutes
Chain — 16 amino acids
Type Biguanide (C4H11N5) Mitochondrial-derived peptide (MDP)
Key Benefits
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
MOTS-c
01 Enhanced insulin sensitivity (~30% improvement)
02 Improved glucose metabolism and tolerance
03 AMPK pathway activation
04 Mitochondrial function optimization
05 Exercise performance enhancement (12-15% improvement)
06 Potential lifespan extension (6.4% median increase in mice)
Dosing Protocols
Metformin
500-2000 mg/day / 1-2x daily with meals
MOTS-c
Start 5mg daily, increase to 10-15mg based on goals / Daily for metabolic support, or 3x weekly for anti-aging
Metabolic health 5-10mg Once daily
Anti-aging protocol 15mg 3x weekly
Exercise performance 10-15mg Pre-workout
Conservative start 5mg Once daily
Side Effects
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
MOTS-c
Generally well-tolerated in animal studies with minimal side effects
Mild injection site reactions (redness, swelling)
Contraindications
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Pregnancy or breastfeeding
WADA prohibited substance (banned for athletic competition)
Limited long-term human safety data
Research Evidence
Metformin MOTS-c
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest 2023 August 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.